Oncimmune Holdings plc (ONC.L) Research

Oncimmune Holdings plc specializes in creating and bringing to market advanced diagnostic technologies for cancer, serving regions across the United Kingdom, North America, Europe, and globally. A cornerstone product is EarlyCDT-Lung, an immunodiagnostic test specifically designed for the detection and identification of lung cancer. The company further advances its capabilities with SeroTag, a robust platform dedicated to discovering and validating biomarkers vital for patient stratification across numerous cancer types, infectious ailments, and a range of autoimmune disorders. Additionally, they provide NavigAID, a bespoke panel for disease characterization. Founded in 2015, Oncimmune Holdings plc operates from its base in Nottingham, UK.

Market snapshot

Symbol
ONC.L
Price
$1.14
Day change
-4.20%
Market cap
$1.3M
P/E ratio
-0.23x
52-week range
0.0114-31
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Destiny Pharma plc (DEST.L)
  • DeepVerge plc (DVRG.L)
  • Hellenic Dynamics Plc (HELD.L)
  • Kanabo Group Plc (KNB.L)
  • LungLife AI, Inc. (LLAI.L)
  • LungLife AI, Inc. (LLA.L)
  • Oxford Cannabinoid Technologies Holdings Plc (OCTP.L)
  • Ovoca Bio plc (OVB.L)

Open Oncimmune Holdings plc (ONC.L) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.